| Drug General Information |
| Drug ID |
D03FUO
|
| Former ID |
DIB004022
|
| Drug Name |
GDC-0834
|
| Drug Type |
Small molecular drug
|
| Indication |
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]
|
Terminated |
[1]
|
|---|
| Company |
CGI Pharmaceuticals Inc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C33H36N6O3S
|
| Canonical SMILES |
c12c(cc(s1)C(=O)Nc1c(c(ccc1)c1cn(c(=O)c(n1)Nc1ccc(cc1)[<br />C@H]1N(CCN(C1=O)C)C)C)C)CCCC2
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase BTK |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Platelet activation
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Primary immunodeficiency
|
|
PANTHER Pathway
|
B cell activation
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
FAS (CD95) signaling pathway
|
|
Class I PI3K signaling events
|
|
EPO signaling pathway
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
DAP12 signaling
|
|
FCERI mediated Ca+2 mobilization
|
|
MyD88 deficiency (TLR2/4)
|
|
IRAK4 deficiency (TLR2/4)
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
WikiPathways
|
Kit receptor signaling pathway
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Signaling by the B Cell Receptor (BCR)
|
|
DAP12 interactions
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
Regulation of toll-like receptor signaling pathway
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011 Jul;338(1):154-63. |
|---|
